Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ACAD 
ACADIA Pharmaceuticals Inc (ACAD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: ACAD (3-star) is a SELL. SELL since 2 days. Simulated Profits (37.59%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $30.32
1 Year Target Price $30.32
| 7 | Strong Buy |
| 6 | Buy |
| 6 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 42.56% | Avg. Invested days 54 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.98B USD | Price to earnings Ratio 17.75 | 1Y Target Price 30.32 |
Price to earnings Ratio 17.75 | 1Y Target Price 30.32 | ||
Volume (30-day avg) 20 | Beta 0.75 | 52 Weeks Range 13.40 - 26.65 | Updated Date 09/14/2025 |
52 Weeks Range 13.40 - 26.65 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 21.8% | Operating Margin (TTM) 12.24% |
Management Effectiveness
Return on Assets (TTM) 5.28% | Return on Equity (TTM) 33.18% |
Valuation
Trailing PE 17.75 | Forward PE 22.94 | Enterprise Value 3277593514 | Price to Sales(TTM) 3.91 |
Enterprise Value 3277593514 | Price to Sales(TTM) 3.91 | ||
Enterprise Value to Revenue 3.22 | Enterprise Value to EBITDA 31.53 | Shares Outstanding 168712000 | Shares Floating 115869866 |
Shares Outstanding 168712000 | Shares Floating 115869866 | ||
Percent Insiders 0.55 | Percent Institutions 103.22 |
Upturn AI SWOT
ACADIA Pharmaceuticals Inc
Company Overview
History and Background
ACADIA Pharmaceuticals Inc. was founded in 1993. Initially focused on discovering drugs for neurodegenerative disorders, it later shifted its focus to neuropsychiatric disorders. A significant milestone was the FDA approval of Nuplazid in 2016, marking its transition to a commercial-stage company.
Core Business Areas
- Neurology: Focuses on developing and commercializing therapies for neurological disorders, including Parkinson's disease psychosis.
- Psychiatry: Focuses on developing and commercializing therapies for psychiatric disorders, including major depressive disorder.
Leadership and Structure
The leadership team includes the CEO, Chief Medical Officer, and heads of various departments like research and development, commercial operations, and finance. The organizational structure is hierarchical, with departments reporting to senior management.
Top Products and Market Share
Key Offerings
- Nuplazid (pimavanserin): Nuplazid is used to treat hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA holds a dominant market share in the PDP treatment space. Competitors include generic antipsychotics, though Nuplazid is the only FDA-approved drug for PDP. 2023 Nuplazid net sales: $597.8 million.
- Daybue (trofinetide): Daybue is used to treat Rett syndrome in adults and children 2 years of age and older. Competitors include symptomatic therapies. Daybue was approved by the FDA in March 2023.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. It involves research, development, manufacturing, and marketing of drugs. Demand is driven by aging populations and increasing prevalence of chronic diseases.
Positioning
ACADIA is positioned as a specialty pharmaceutical company focusing on innovative therapies for central nervous system disorders. Its competitive advantage lies in its focus on underserved markets and its proprietary drug development platform.
Total Addressable Market (TAM)
The TAM for neurological and psychiatric disorders is significant and growing. ACADIA is well-positioned to capture a portion of this TAM through its targeted therapies. Estimates put the PDP market at several billion dollars, with Rett syndrome having a smaller but still substantial TAM.
Upturn SWOT Analysis
Strengths
- FDA-approved products
- Proprietary drug development platform
- Strong market position in PDP
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- Dependence on patent protection
- High research and development costs
- Regulatory risks
Opportunities
- Expanding product pipeline
- Geographic expansion
- Acquisitions and partnerships
- New indications for existing products
Threats
- Competition from other pharmaceutical companies
- Generic entry of Nuplazid
- Unfavorable regulatory changes
- Product liability litigation
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- ITCI
Competitive Landscape
ACADIA's advantage lies in its FDA-approved therapies for underserved markets. Disadvantages include reliance on a limited product portfolio and competition from generic drugs.
Growth Trajectory and Initiatives
Historical Growth: ACADIA has experienced significant revenue growth following the approval and commercialization of Nuplazid. Daybue represents additional growth catalyst.
Future Projections: Analysts project continued revenue growth driven by increased Nuplazid sales and Daybue market penetration. Profitability is expected to improve as revenue scales.
Recent Initiatives: Recent initiatives include expanding the label for Nuplazid, the commercial launch of Daybue, and advancing pipeline programs.
Summary
ACADIA Pharmaceuticals is a growing specialty pharmaceutical company with a focus on central nervous system disorders. The commercialization of Nuplazid and Daybue drives growth, but high R&D costs contribute to ongoing net losses. The company must manage regulatory risks, competition, and potential generic entry of Nuplazid while continuing to expand its pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ACADIA Pharmaceuticals Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data are estimates and may vary. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ACADIA Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2004-05-27 | CEO & Director Ms. Catherine E. Owen Adams | ||
Sector Healthcare | Industry Biotechnology | Full time employees 653 | Website https://www.acadia.com |
Full time employees 653 | Website https://www.acadia.com | ||
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.